29 June 2012
Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes
Jerzy NożyńskiABCDEF, Michał ZakliczyńskiACDEFG, Dominika Konecka-MrowkaAC, Teresa ZielinskaB, Helena ZakliczynskaE, Barbara NikielB, Joanna Mlynarczyk-LiszkaB, Andrzej MrowkaB, Ewa Zembala-NozynskaD, Marta PijetE, Kinga RdzanowskaE, Dariusz LangeE, Roman PrzybylskiB, Marian ZembalaFDOI: 10.12659/AOT.883223
Ann Transplant 2012; 17(2): 53-61
Abstract
Background: Non-enzymatic coupling of protein and lipid cellular structures with glucose leading to the formation of advanced glycation end products (AGE) plays a role in aging and the development of diabetic complications, but its contribution to myocardial pathology is unclear. We aimed to assess the role of heart failure on AGE formation in patients with or without diabetes mellitus type 2 (DM2).
Material/Methods: Heart tissue specimens from 136 patients undergoing transplantation were grouped as follows: 14 cases of ischemic cardiomyopathy (ICM) and DM2, 8 cases of dilated cardiomyopathy (DCM) and DM2, 67 cases of ICM without DM2, and 47 cases of DCM without DM2. Fourteen heart samples were from the autopsies of patients with DM2 without heart disease, and 20 heart samples were from organ donors in whom the heart was wasted. AGE deposits were localized immunohistochemically counted using a semiquantitative scale and characterized by their staining pattern.
Results: Positive staining was present in all samples from both cardiomyopathy groups with DM2, in 71% of healthy hearts from the DM2 subjects, in 51% of ICM non-diabetic hearts, and in 38% of DCM non-diabetic hearts, and in only 15% of the organ donors. Mixed-diffuse and granular AGE patterns were characteristic for DM2, while a diffuse pattern was more frequently observed in heart failure patients without diabetes. The semiquantitative results supported increased AGE accumulation in patients with DM2 and/or cardiomyopathy.
Conclusions: The amount of AGE in cardiomyocytes increases significantly in both diabetes and heart failure, with a staining pattern typical for each condition.
Keywords: diabetes, advanced glycation end products
In Press
Original article
The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival Afte...Ann Transplant In Press; DOI: 10.12659/AOT.945249
Original article
Biopsychosocial Effects of Donor Traits on Heart Transplant RecipientsAnn Transplant In Press; DOI:
Clinical Research
Ten-Year Retrospective Analysis of Continuous Renal Replacement Therapy in Burn Patients: Impact on Surviva...Ann Transplant In Press; DOI:
Original article
Factors Influencing Stress Disorders in Intensive Care Unit (ICU) Patients After Liver Transplantation: A C...Ann Transplant In Press; DOI: 10.12659/AOT.944320
Most Viewed Current Articles
05 Apr 2022 : Original article 13,113
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 10,260
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,611
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,271
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860